Arcutis Biotherapeutics ARQT 深 滬
已收盤 08-08 16:00:00 美东时间
14.77
+0.650
+4.60%
華盛通- 最 高14.795
- 今 開14.03
- 成交量 261.35万股
- 最 低 13.695
- 昨 收 14.12
- 總市值 17.58亿
- 52周最高 17.75
- 市盈率 靜 --
- 換手率 2.20%
- 52周最低 8.03
- 委 比 -8.18%
- 總股本 1.19亿
- 歷史最高 40.88
- 量 比 1.18
- 振 幅 7.79%
- 歷史最低 1.76
- 每 手 1
- 風險率 2.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $22
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $20 to $22.
08-07 18:34
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report second quarter 2025 financial results and provide a business update on August 6, 2025. A conference call and webcast will be held at 4:30 p.m. ET the same day, and the webcast will be available on the Company’s website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases with a portfolio of advanced targeted topicals.
07-23 20:00
Arcutis Biotherapeutics' ZORYVE cream 0.15% received recommendation in focused guideline update for management of adult AD from AAD.
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects
06-26 20:08
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation from the American Academy of Dermatology for adults with mild to moderate atopic dermatitis (AD). As a next-generation, steroid-free topical PDE4 inhibitor, ZORYVE is the first FDA-approved branded treatment for AD, plaque psoriasis, and seborrheic dermatitis. It offers clinically meaningful improvements in disease severity and pruritus with favorable safety and tolerability. ...
06-26 12:00
华东医药创新皮肤外用制剂0.3%罗氟司特泡沫（ZORYVE）脂溢性皮炎III期临床试验申请获NMPA批准
转自：华东医药股份有限公司 2025年6月9日，华东医药股份有限公司（以下简称“公司”）全资子公司杭州中美华东制药有限公司（以下简称“中美华东”）收到国家药品监...
06-11 19:18
华东医药(000963.SZ)：中美华东0.3%罗氟司特泡沫临床试验申请获批
华东医药(000963.SZ)发布公告，2025 年6月9日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的...
06-10 21:43
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics, Inc. has initiated a Phase 2 study, INTEGUMENT-INFANT, to assess the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to 24 months with atopic dermatitis (AD). AD affects approximately 9.6 million children in the U.S., with 60% of cases developing symptoms within the first year of life. ZORYVE, a highly potent PDE4 inhibitor, is being evaluated as a potential long-term treatment for inf...
06-10 12:00
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements
New phase 3 data released by Arcutis Biotherapeutics (NASDAQ:ARQT) on Zoryve (roflumilast) found that the cream leads to durable improvement in of atopic dermatitis symptoms over the long term. Result...
06-06 21:34
Arcutis To Present New Long-Term Results Of ZORYVE Cream at 2025 Revolutionizing Atopic Dermatitis Conference
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with
06-06 20:03
